MTOR and breast cancer: Furthermore, it corroborates the hypothesis that the AMPK/mTOR pathway plays a role in the development of resistance to endocrine therapy in ER + BC and that the metformin activity on the AMPK/mTOR pathway can re-sensitise the ER + BCs to endocrine therapy [52].